Colorectal Cancer Articles

Expert Discusses Ongoing Advances With Immunotherapy in CRC
Tanios Bekaii-Saab, MD, discusses the emerging role of immunotherapy in patients with MSI-H colorectal cancer. 
Grothey Highlights Biomarker Research in CRC
Axel Grothey, MD, discusses current first-line treatments for patients with CRC and the importance of developing biomarkers for this population.
Therapies in Development to Improve Outcomes in BRAF-Mutated CRC
Tim G. Larson, MD, discusses emerging data involving immunotherapy for patients with microsatellite instability (MSI)/microsatellite stable (MSS) colorectal cancer (CRC) and highlighted some of the identified molecular mutations in patients with CRC
Expert Reflects on Recent Trial Results in CRC and Small Bowel Cancer
Heinz-Josef Lenz, MD, discusses his study of molecular variations between small bowel adenocarcinomas, right-sided colon cancers, and gastroesophageal cancers.
FDA Approves First Biosimilar for Cancer Treatment
The FDA approved the first biosimilar for the treatment of cancer. ABP-215 (bevacizumab-awwb; Mvasi), a biosimilar for bevacizumab (Avastin), is indicated for the treatment of colorectal, lung, brain, kidney, and cervical cancers in adult patients.
An Impactful Year for Molecular Testing in GI Cancers
Antonia R. Sepulveda, MD, PhD, discusses the importance and utility of genetic testing in GI cancers, as well as noteworthy developments in microsatellite instability, BRAF, and KRAS testing in colorectal cancer.
FIT Assay Shows Overall Diagnostic Accuracy for CRC
Researchers have concluded from an analysis of multiple studies that the fecal immunochemical test has high overall diagnostic accuracy for screening asymptomatic patients at an increased risk for colorectal cancer (CRC) and moderate accuracy for diagnosing advanced neoplasia (AN).
Manuel Hidalgo, MD, discusses his insight on the growth of genetic testing in CRC.
Biomarker Basics: A Look at MSI's Growing Role
The recent approval of 2 immunotherapies for the treatment of certain patients with tumors that exhibit microsatellite instability has propelled the emerging biomarker into clinical practice, prompting calls for broader genetic testing.
The FDA has granted an accelerated approval to nivolumab for the treatment of adult and pediatric patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
Publication Bottom Border
Border Publication